We are thrilled to announce a significant milestone for PL BioScience! In a recent press release, we reveal that we have successfully closed a €7.8 million Series A financing round.
This Series A funding marks a pivotal moment in our company’s growth journey. This substantial infusion of capital represents the fruits of our labor in building trust among the scientific community, and will go a long way towards helping us achieve our mission of a xeno-free cell culture future.
Strategic Benefits of the financing:
- Ability to scale up our manufacturing capabilities and ensure ample and consistent availability of human platelet lysate (HPL).
- Support our research and development pipeline for innovative new HPL products.
- Expand our reach globally and solidify our position as a leading provider of HPL worldwide.
Read the full press release here.
We have come a long way since our humble start, and would like to wish all our customers and partners a big thank you for your ongoing trust and support!
